| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8239080 | International Journal of Radiation Oncology*Biology*Physics | 2008 | 6 Pages |
Abstract
Hypofractionated radiation with neoadjuvant and concomitant hormone therapy is well tolerated with no significant short- or long-term morbidity. Control for this risk group is good, and comparative Phase III studies should be undertaken to determine whether this treatment is superior to new evolving treatments.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Michael M.D., Bernard M.D., Marie-Andrée M.D., Carole M.D., Thu M.D., Jean-Paul M.D.,